tetano
Editor, Senior Moderator
Respir Med Case Rep
. 2023;43:101857.
doi: 10.1016/j.rmcr.2023.101857. Epub 2023 Apr 25. Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease triggered by COVID-19: What is the best practice for treatment?
Toshiyuki Yonezawa[SUP] 1 2 [/SUP], Atsushi Suzuki[SUP] 2 3 [/SUP], Kensuke Fukumitsu[SUP] 2 4 [/SUP], Takuma Katano[SUP] 1 2 [/SUP], Hisashi Kako[SUP] 2 5 [/SUP], Makoto Ishii[SUP] 3 [/SUP], Akio Niimi[SUP] 4 [/SUP], Kazuyoshi Imaizumi[SUP] 5 [/SUP], Koji Sakamoto[SUP] 3 [/SUP], Norihito Omote[SUP] 3 [/SUP], Etsuro Yamaguchi[SUP] 1 2 [/SUP]
Affiliations
We present a case of 79-year-old female with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) developed an acute exacerbation (AE) triggered by coronavirus disease 2019 (COVID-19). The patient was unresponsive to a combination therapy of remdesivir, dexamethasone, and tocilizumab. Given that a recent multicenter cohort study reported ILD as a poor prognostic contributor in patients with RA and COVID-19, there may be potentially a certain number of patients with AE of RA-ILD triggered by COVID-19. This case highlights the need for a discussion how to treat these patients in a daily clinical practice.
Keywords: Acute exacerbation; COVID-19; Interstitial lung diseases; Rheumatoid arthritis; Treatment.
. 2023;43:101857.
doi: 10.1016/j.rmcr.2023.101857. Epub 2023 Apr 25. Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease triggered by COVID-19: What is the best practice for treatment?
Toshiyuki Yonezawa[SUP] 1 2 [/SUP], Atsushi Suzuki[SUP] 2 3 [/SUP], Kensuke Fukumitsu[SUP] 2 4 [/SUP], Takuma Katano[SUP] 1 2 [/SUP], Hisashi Kako[SUP] 2 5 [/SUP], Makoto Ishii[SUP] 3 [/SUP], Akio Niimi[SUP] 4 [/SUP], Kazuyoshi Imaizumi[SUP] 5 [/SUP], Koji Sakamoto[SUP] 3 [/SUP], Norihito Omote[SUP] 3 [/SUP], Etsuro Yamaguchi[SUP] 1 2 [/SUP]
Affiliations
- PMID: 37124053
- PMCID: PMC10125217
- DOI: 10.1016/j.rmcr.2023.101857
We present a case of 79-year-old female with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) developed an acute exacerbation (AE) triggered by coronavirus disease 2019 (COVID-19). The patient was unresponsive to a combination therapy of remdesivir, dexamethasone, and tocilizumab. Given that a recent multicenter cohort study reported ILD as a poor prognostic contributor in patients with RA and COVID-19, there may be potentially a certain number of patients with AE of RA-ILD triggered by COVID-19. This case highlights the need for a discussion how to treat these patients in a daily clinical practice.
Keywords: Acute exacerbation; COVID-19; Interstitial lung diseases; Rheumatoid arthritis; Treatment.